Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jul 9;13(1):2373519. doi: 10.1080/2162402X.2024.2373519

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

PMC Copyright notice

Figure 6. — Nivolumab plus urelumab plus anti-TGF-β stimulate IFNγ secretion in a fraction of tumor-derived fragments from cancer patients.

a) Experimental design with fragments that were cryopreserved prior to the cultures under the influence of the indicated color-coded stimuli. A series of six cases of endometrial, ovarian and renal tumors were tested (Table S1). b) IFNγ release into the supernatants by the fragments under the indicated color-coded tissue culture conditions. PDTFs: patient-derived tumor fragments.